IKZF3 Antibody - #DF3472

(1)   (2)  
Product: IKZF3 Antibody
Catalog: DF3472
Description: Rabbit polyclonal antibody to IKZF3
Application: WB IF/ICC
Reactivity: Human, Mouse
Prediction: Rat, Pig, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 62 KD; 58kD(Calculated).
Uniprot: Q9UKT9
RRID: AB_2835836

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Rat(%), Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Xenopus(90%)
Clonality:
Polyclonal
Specificity:
IKZF3 Antibody detects endogenous levels of total IKZF3.
RRID:
AB_2835836
Cite Format: Affinity Biosciences Cat# DF3472, RRID:AB_2835836.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AIO; Aiolos; IKAROS family zinc finger 3 (Aiolos); IKAROS family zinc finger 3; Ikaros family zinc finger protein 3; IKZF 3; IKZF3; IKZF3_HUMAN; zinc finger DNA binding protein Aiolos; Zinc finger protein Aiolos; Zinc finger protein subfamily 1A 3 (Aiolos); Zinc finger protein subfamily 1A 3; Zinc finger protein subfamily 1A, member 3; ZNFN1A3;

Immunogens

Immunogen:
Uniprot:

Q9UKT9(IKZF3_HUMAN) >>Visit HPA database.

Gene(ID):
IKZF3(22806)
Expression:
Q9UKT9 IKZF3_HUMAN:

Expressed most strongly in peripheral blood leukocytes, the spleen, and the thymus.

Sequence:
MEDIQTNAELKSTQEQSVPAESAAVLNDYSLTKSHEMENVDSGEGPANEDEDIGDDSMKVKDEYSERDENVLKSEPMGNAEEPEIPYSYSREYNEYENIKLERHVVSFDSSRPTSGKMNCDVCGLSCISFNVLMVHKRSHTGERPFQCNQCGASFTQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDALTGHLRTHSVEKPYKCEFCGRSYKQRSSLEEHKERCRTFLQSTDPGDTASAEARHIKAEMGSERALVLDRLASNVAKRKSSMPQKFIGEKRHCFDVNYNSSYMYEKESELIQTRMMDQAINNAISYLGAEALRPLVQTPPAPTSEMVPVISSMYPIALTRAEMSNGAPQELEKKSIHLPEKSVPSERGLSPNNSGHDSTDTDSNHEERQNHIYQQNHMVLSRARNGMPLLKEVPRSYELLKPPPICPRDSVKVINKEGEVMDVYRCDHCRVLFLDYVMFTIHMGCHGFRDPFECNMCGYRSHDRYEFSSHIARGEHRALLK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Xenopus
90
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9UKT9 As Substrate

Site PTM Type Enzyme
S57 Phosphorylation
S65 Phosphorylation
K73 Ubiquitination
S74 Phosphorylation
S90 Phosphorylation
Y96 Phosphorylation
K100 Sumoylation
K100 Ubiquitination
S115 Phosphorylation
T141 Phosphorylation
K158 Ubiquitination
T169 Phosphorylation
K172 Sumoylation
K200 Ubiquitination
K203 Ubiquitination
K221 Ubiquitination
K245 Acetylation
K245 Sumoylation
K245 Ubiquitination
S261 Phosphorylation
K265 Ubiquitination
K273 Ubiquitination
Y286 Phosphorylation
Y290 Phosphorylation
T326 Phosphorylation
S352 Phosphorylation
K361 Ubiquitination
K362 Ubiquitination
K369 Ubiquitination
S378 Phosphorylation
K419 Ubiquitination
K429 Ubiquitination
K444 Ubiquitination

Research Backgrounds

Function:

Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner.

PTMs:

Phosphorylation on tyrosine residues induced by IL2 is required for dissociation from HRAS and nuclear translocation of IKZF3 in T-cells. Phosphorylation on tyrosine residues induced by IL4 is required for dissociation from Bcl-X(L) in T-cells.

Subcellular Location:

Nucleus. Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed most strongly in peripheral blood leukocytes, the spleen, and the thymus.

Subunit Structure:

Homodimer, and heterodimer with other IKAROS family members. Interacts with IKZF4 AND IKZF5. Interacts with IKZF1. Interacts with HRAS. Interacts with FOXP3; this interaction may be required for silencing target genes and regulating the suppressive activity of FOXP3-positive regulatory T-cells (Treg). Interacts with BCL21L isoform Bcl-X(L); this interaction blocks the anti-apoptotic role of BCL21L. Associates with histone deacetylase complexes containing HDAC1, MTA2 and SIN3A.

Family&Domains:

Belongs to the Ikaros C2H2-type zinc-finger protein family.

References

1). Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells. OncoTargets and Therapy, 2021 (PubMed: 34262292) [IF=4.0]

Application: WB    Species: Human    Sample: ARP-1 and RPMI-8226 cells

Figure 5 Chidamide (CHI)-induced ROS accumulation enhances anti-myeloma effect of lenalidomide (Len) through elevating H2O2. (A and B) ARP-1 and RPMI-8226 cells were treated with different doses of lenalidomide (0, 5 and 20 μM) for indicated time (0, 3, 6 and 12 hours), pretreated with or without 15 mmol/L NAC. Then ROS levels were measured using Reactive Oxygen Species Assay Kit. NS, p > 0.05; *, p < 0.05; **, p < 0.01. (C and D) ARP-1 and RPMI-8226 cells were treated with different doses of lenalidomide (0, 5 and 20 μM) for 12 hours, or 1 μM chidamide and 20 μM lenalidomide for 6 hours. Then H2O2 levels were tested using hydrogen peroxide assay kit. (E and F) after treated with 1 μM chidamide, 20 μM lenalidomide or H2O2 (100 and 500 μM) for 6 hours, expression of IKZF1 and IKZF3 were determined using Western blotting in ARP-1 and RPMI-8226 cells. (G and H) pretreated with or without 15 mmol/L NAC, ARP-1 and RPMI-8226 cells were then treated with 1 μM chidamide, 20 μM lenalidomide or 20 μM H2O2 for 24 hours, and CCK-8 assays were used to evaluate the cell viability. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.